TRIP6 expression is up-regulated in glioma cells and tissues and its overexpression is correlated with poor clinical outcomes of glioma patients, which indicates that TRIP6 may become a novel prognostic biomarker and therapeutic target of glioma [10]. Here, TRIP6 is linked to central nervous system cancer.